SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as a community-driven meme project that is consistently trending on social platforms without an official chart, fueling intense community speculation about an upcoming breakout. Holders are actively discussing milestone targets for market capitalization and expressing strong commitment to the project's long-term growth and cultural branding.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending following a significant upgrade from Bank of America, which cited the company's transformation into an optical infrastructure powerhouse well-positioned to capitalize on AI-driven data center demand. Investors are actively discussing the stock's growth potential, fueled by its recent acquisition of Infinera, strategic partnerships with companies like Nvidia, and an improved competitive standing against European rivals.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors react to the company securing over $4 million in government contracts for quantum materials and lasers, sparking a debate between those betting on long-term technological validation and those skeptical of the company's path to high-volume commercialization. Community discourse is heavily focused on the stock's low float and short interest, fueling speculation of potential volatility and high-reward upside as the company aims to scale its semiconductor integration platform for AI and defense applications.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs shares are facing selling pressure as investors react to the resignation of the firm's top lawyer over ties to Jeffrey Epstein. The community is actively debating the implications of these reputational risks while technical traders monitor the stock's recent break below key support levels.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest strong topline results from its Phase 3 RASolute 302 clinical trial, triggering significant price appreciation and active discussion regarding the company's future as a potential buyout target. Community sentiment remains highly bullish, with many highlighting the stock's robust cash position and the transformative potential of its daraxonrasib treatment for pancreatic cancer.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors debate the potential for a buyout or aggressive turnaround, fueled by persistent short interest and frustration over the board's delay in naming a permanent CEO. While some market participants see deep value in the brand's international expansion and high dividend yield, others remain skeptical, pointing to lackluster domestic performance and operational challenges.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the companys electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing explosive, meme-like volatility and parabolic price action as retail traders and institutional flows surge ahead of the company's upcoming inclusion in the Nasdaq-100. Community sentiment is deeply polarized, with bulls chasing momentum fueled by AI-driven memory demand and rumors of a stock split, while skeptics warn of an overextended bubble nearing a potential distribution top.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility driven by a massive short squeeze that has triggered a cascade of liquidations for traders betting against the token. The community is actively debating the project's rapid valuation growth and its potential as a decentralized music entertainment protocol, with many highlighting recent exchange listings and upcoming event roadmap milestones as catalysts for continued momentum.

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

ImageneBio Inc.

ImageneBio, Inc.

ImageneBio, Inc. is trending as investors weigh significant institutional backing and cash-rich financials against long-term development timelines for its lead drug candidates targeting atopic dermatitis and alopecia. The community is actively debating the potential for a technical breakout amid high volatility, with many focused on how the company's valuation compares to its cash reserves and pipeline potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Daraxonrasib significantly improved both progression-free and overall survival compared to standard chemotherapy.</li><li>Patients treated with the drug lived a median of 13.2 months, compared with 6.7 months for those on chemotherapy.</li><li>The firm stated that the study met all key endpoints.</li></ul>Revolution Medicines (RVMD) drew the spotlight after its shares surged 36% on Monday morning, driven by strong Phase 3 results for its experimental drug Daraxonrasib to treat metastatic pancreatic cancer.<h2 class="st-heading-2">Trial Shows Better Results Than Standard Chemotherapy</h2>In the RASolute 302 trial, Daraxonrasib significantly improved both progression-free and overall survival compared to standard chemotherapy. Patients treated with the drug lived a median of 13.2 months, compared with 6.7 months for those on chemotherapy, highlighting a meaningful benefit. The treatment was also generally well tolerated, with no new safety concerns reported.The study met all key endpoints, and the company plans to submit the data to the U.S. Food and Drug Administration (FDA) and present it at the American Society of Clinical Oncology Annual Meeting in May.“These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape,” said Mark A. Goldsmith, CEO and chairman of Revolution Medicines.<h2 class="st-heading-2">Daraxonrasib Targets RAS-Driven Tumors</h2>Pancreatic cancer is heavily driven by RAS gene mutations, with over 90% of patients affected by these aggressive genetic changes. Daraxonrasib is a new drug designed to target a broad range of RAS-driven tumors.In the trial, patients received either a daily oral dose of Daraxonrasib or standard chemotherapy chosen by doctors. The study mainly measured progression-free and overall survival in patients with specific RAS mutations, while also tracking results across all participants. It also evaluated response rates, duration of benefit, and quality of life.While Daraxonrasib has not yet been approved in the U.S. or Europe, it has received special designations from the FDA to expedite its development for pancreatic cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/RVMD">RVMD</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes.Users spoke about a potential buyout following the results.<stembedurl>https://stocktwits.com/TH76/message/650101082</stembedurl><stembedurl>https://stocktwits.com/Ccg_/message/650101993</stembedurl>RVMD shares have gained more than 220% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Revolution Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

RVMD Stock Surges To All-Time Highs After 36% Jump – What’s Driving This Super Rally?

The company reported robust Phase 3 results for its Daraxonrasib drug to treat metastatic pancreatic cancer.

Equity

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial...

Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer

Former Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic cancer...

Revolution Medicines Target of Unusually Large Options Trading (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) was the target of some unusual options trading activity on Friday. Investors acquired 25,539 put options on the company. This represents an...

Aberdeen Group plc Makes New $9.02 Million Investment in Revolution Medicines, Inc. $RVMD

Aberdeen Group plc purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and...

Tema Etfs LLC Decreases Position in Revolution Medicines, Inc. $RVMD

Tema Etfs LLC trimmed its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 20.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange...

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) have been given a consensus rating of "Buy" by the twenty-one ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, fifteen have given...

Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) was the target of unusually large options trading activity on Friday. Stock investors bought 12,797 put options on the company. This represents an increase of 131% compared to the average daily volume of 5,546 put options...

Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,073 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Lin Wei sold 2,073 shares of the firm's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the completion of the transaction, the insider...

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Investors are celebrating positive Phase 3 clinical trial results that show significant survival benefits for the drug daraxonrasib in pancreatic cancer patients.

Market participants are speculating on a potential acquisition due to the company's strong cash position and transformative clinical trial success.

The success in targeting previously 'undruggable' mutations has shifted attention toward the competitive landscape of the RAS and KRAS innovation frontier.

RVMD
Revolution Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RVMD News

RVMDRevolution Medicines Inc